ERYTECH PHARMA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.10.23	PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains (GlobeNewswire)
04.10.23	PHAXIAM Receives Compliance Notice from Nasdaq (GlobeNewswire)
03.10.23	PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration (GlobeNewswire)
26.09.23	Rapport Financier Semestriel 30 Juin 2023 PHAXIAM (GlobeNewswire)
21.09.23	PHAXIAM Provides Business and Financial Update For the First Half of 2023 (GlobeNewswire)
19.09.23	PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target (GlobeNewswire)
18.09.23	PHAXIAM Therapeutics announces the completion of its reverse share split (GlobeNewswire)
08.09.23	Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2023 (GlobeNewswire)
05.09.23	PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences (GlobeNewswire)
08.08.23	Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023 (GlobeNewswire)
27.07.23	PHAXIAM Therapeutics announces a reverse share split of its shares (GlobeNewswire)
28.06.23	Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM (GlobeNewswire)
27.06.23	Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023 (GlobeNewswire)
26.06.23	ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics (GlobeNewswire)
23.06.23	ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 (GlobeNewswire)
20.06.23	ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit (GlobeNewswire)
14.06.23	ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma (GlobeNewswire)
13.06.23	Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023 (GlobeNewswire)
12.06.23	ERYTECH Responds to Akkadian’s Disinformation (GlobeNewswire)
05.06.23	ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes (GlobeNewswire)
24.05.23	ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023 (GlobeNewswire)
23.05.23	ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes (GlobeNewswire)
16.05.23	Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023 (GlobeNewswire)
15.05.23	ERYTECH Provides Update on the Announced Combination with PHERECYDES (GlobeNewswire)
12.05.23	Monthly information related to total number of voting rights and shares composing the share capital _April 30, 2023 (GlobeNewswire)
09.05.23	ERYTECH Provides Business and Financial Update for the First Quarter of 2023 (GlobeNewswire)
17.04.23	ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market (GlobeNewswire)
12.04.23	Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023 (GlobeNewswire)
22.03.23	ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
06.03.23	Monthly information related to total number of voting rights and shares composing the share capital _February 28, 2023 (GlobeNewswire)
15.02.23	ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies (GlobeNewswire)
09.02.23	Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023 (GlobeNewswire)
21.11.22	ERYTECH Provides Business and Financial Update for the Third Quarter of 2022 (GlobeNewswire)
13.10.22	ERYTECH Announces Receipt of Nasdaq Notice (GlobeNewswire)
04.10.22	Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022 (GlobeNewswire)
12.09.22	ERYTECH Provides Business and Financial Update for the First Half of 2022 (GlobeNewswire)
06.09.22	Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022 (GlobeNewswire)
06.09.22	Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022 (GlobeNewswire)
24.08.22	ERYTECH Provides Regulatory Update (GlobeNewswire)
07.07.22	Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022. (GlobeNewswire)
24.06.22	Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022 (GlobeNewswire)
03.06.22	Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022. (GlobeNewswire)
24.05.22	ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 (GlobeNewswire)
17.05.22	ERYTECH to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
13.05.22	Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022 (GlobeNewswire)
12.05.22	ERYTECH Provides Business and Financial Update for the First Quarter of 2022 (GlobeNewswire)
28.04.22	ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar (GlobeNewswire)
25.04.22	ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent (GlobeNewswire)
06.04.22	ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology (GlobeNewswire)
06.04.22	Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2022 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	250.00	1.05 %	K V
Zurich Insur Gr	538.20	0.98 %	K V
Swiss Re	129.70	0.93 %	K V
UBS Group	26.95	0.90 %	K V
Givaudan	3’951.00	0.87 %	K V
Part Grp Hldg	1’214.00	0.25 %	K V
Sonova Hldg	296.10	0.17 %	K V
Nestle	74.10	0.16 %	K V
Sika	213.10	-0.05 %	K V
Geberit	511.40	-0.54 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ERYTECH PHARMA

Aktien Top/Flop

Meistgelesene Nachrichten